Arch Biopartners Inc. (ARCH.V)
CAD 1.73
(-0.57%)
CAD 1.73
(-0.57%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -430.71 Thousand CAD | 60.12% |
| 2022 | -101.42 Thousand CAD | -21.14% |
| 2021 | -77.01 Thousand CAD | 80.0% |
| 2020 | -4.45 Million CAD | -97.99% |
| 2019 | - CAD | 28.92% |
| 2018 | -15.31 Thousand CAD | -68.45% |
| 2017 | -22.91 Thousand CAD | -91.8% |
| 2016 | -26.37 Thousand CAD | -10.32% |
| 2015 | -820.93 Thousand CAD | -176.9% |
| 2014 | -381.46 Thousand CAD | -86.34% |
| 2013 | -174.92 Thousand CAD | 45.23% |
| 2012 | -314.51 Thousand CAD | 23.66% |
| 2011 | -438.53 Thousand CAD | 94.28% |
| 2010 | -7.21 Million CAD | -54.8% |
| 2009 | -4.65 Million CAD | -920.3% |
| 2008 | -268.34 Thousand CAD | -142.47% |
| 2007 | -188.19 Thousand CAD | -272.18% |
| 2006 | 109.29 Thousand CAD | 135.91% |
| 2005 | -304.39 Thousand CAD | 70.14% |
| 2004 | -1.02 Million CAD | -156.23% |
| 2003 | -430.09 Thousand CAD | -87.91% |
| 2002 | -505.00 CAD | -126.55% |
| 2001 | 797.52 Thousand CAD | 190.49% |
| 2000 | -881.34 Thousand CAD | -24.57% |
| 1999 | -707.5 Thousand CAD | -51.64% |
| 1998 | -466.55 Thousand CAD | 58.81% |
| 1997 | -1.13 Million CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -1 Million CAD | 0.0% |
| 2024 Q3 | -767.65 Thousand CAD | 96.67% |
| 2024 Q2 | -3.23 Million CAD | 0.0% |
| 2023 Q3 | -474.3 Thousand CAD | 47.07% |
| 2023 FY | - CAD | -385.54% |
| 2023 Q4 | 533.41 Thousand CAD | 212.46% |
| 2023 Q2 | -896.03 Thousand CAD | 58.18% |
| 2023 Q1 | -2.14 Million CAD | -509.19% |
| 2022 Q1 | -108.91 Thousand CAD | -114.46% |
| 2022 Q3 | -196.94 Thousand CAD | 53.38% |
| 2022 FY | - CAD | -21.14% |
| 2022 Q4 | -351.74 Thousand CAD | -78.6% |
| 2022 Q2 | -422.43 Thousand CAD | -287.86% |
| 2021 Q2 | -1.01 Million CAD | 37.03% |
| 2021 FY | - CAD | 80.0% |
| 2021 Q4 | 753.42 Thousand CAD | -22.53% |
| 2021 Q3 | 972.51 Thousand CAD | 195.98% |
| 2021 Q1 | -1.6 Million CAD | -2.82% |
| 2020 Q3 | -2.14 Million CAD | -4213.75% |
| 2020 Q1 | -697.02 Thousand CAD | 25.49% |
| 2020 FY | - CAD | -97.99% |
| 2020 Q4 | -1.56 Million CAD | 27.08% |
| 2020 Q2 | -49.75 Thousand CAD | 92.86% |
| 2019 Q4 | -935.51 Thousand CAD | -4753.51% |
| 2019 Q3 | -19.27 Thousand CAD | 96.01% |
| 2019 FY | - CAD | 28.92% |
| 2019 Q2 | -482.71 Thousand CAD | 40.72% |
| 2019 Q1 | -814.23 Thousand CAD | -7.57% |
| 2018 Q2 | -599.65 Thousand CAD | -81.37% |
| 2018 Q1 | -330.61 Thousand CAD | -54.59% |
| 2018 FY | - CAD | -68.45% |
| 2018 Q4 | -756.91 Thousand CAD | 48.89% |
| 2018 Q3 | -1.48 Million CAD | -146.96% |
| 2017 Q4 | -213.87 Thousand CAD | 83.56% |
| 2017 Q3 | -1.3 Million CAD | -778.39% |
| 2017 FY | - CAD | -91.8% |
| 2017 Q1 | -230.16 Thousand CAD | 32.14% |
| 2017 Q2 | -148.05 Thousand CAD | 35.67% |
| 2016 Q3 | -177.54 Thousand CAD | 41.43% |
| 2016 FY | - CAD | -10.32% |
| 2016 Q1 | -160.73 Thousand CAD | 12.55% |
| 2016 Q2 | -303.11 Thousand CAD | -88.58% |
| 2016 Q4 | -339.17 Thousand CAD | -91.03% |
| 2015 FY | - CAD | -176.9% |
| 2015 Q2 | -187.97 Thousand CAD | 48.27% |
| 2015 Q3 | -153.66 Thousand CAD | 18.25% |
| 2015 Q4 | -183.8 Thousand CAD | -19.61% |
| 2015 Q1 | -363.38 Thousand CAD | -278.36% |
| 2014 Q1 | -49.43 Thousand CAD | 6.09% |
| 2014 Q2 | -53.84 Thousand CAD | -8.93% |
| 2014 Q4 | -96.04 Thousand CAD | 21.07% |
| 2014 FY | - CAD | -86.34% |
| 2014 Q3 | -121.67 Thousand CAD | -125.98% |
| 2013 Q2 | -76.49 Thousand CAD | -162.9% |
| 2013 Q4 | -52.63 Thousand CAD | -274.79% |
| 2013 Q1 | -29.09 Thousand CAD | 67.67% |
| 2013 Q3 | -14.04 Thousand CAD | 81.64% |
| 2013 FY | - CAD | 45.23% |
| 2012 Q2 | -56.68 Thousand CAD | 35.27% |
| 2012 Q4 | -89.98 Thousand CAD | -5.63% |
| 2012 FY | - CAD | 23.66% |
| 2012 Q3 | -85.18 Thousand CAD | -50.26% |
| 2012 Q1 | -87.57 Thousand CAD | -22.16% |
| 2011 Q4 | -71.69 Thousand CAD | 54.99% |
| 2011 FY | - CAD | 94.28% |
| 2011 Q3 | -159.26 Thousand CAD | -106.21% |
| 2011 Q2 | -77.23 Thousand CAD | 25.58% |
| 2011 Q1 | -103.78 Thousand CAD | -101.48% |
| 2010 Q2 | -24.03 Thousand CAD | 75.61% |
| 2010 FY | - CAD | -54.8% |
| 2010 Q4 | 6.99 Million CAD | 24718.43% |
| 2010 Q3 | -28.41 Thousand CAD | -18.19% |
| 2010 Q1 | -98.57 Thousand CAD | -268.27% |
| 2009 Q4 | -26.76 Thousand CAD | -100.57% |
| 2009 FY | - CAD | -920.3% |
| 2009 Q2 | -57.5 Thousand CAD | 86.1% |
| 2009 Q3 | 4.71 Million CAD | 8305.25% |
| 2009 Q1 | -413.6 Thousand CAD | -496.25% |
| 2008 Q4 | 104.37 Thousand CAD | 292.54% |
| 2008 Q3 | -54.21 Thousand CAD | 41.62% |
| 2008 FY | - CAD | -142.47% |
| 2008 Q2 | -92.86 Thousand CAD | 40.06% |
| 2008 Q1 | -154.94 Thousand CAD | -4592.46% |
| 2007 Q2 | -32.39 Thousand CAD | -112.81% |
| 2007 FY | - CAD | -272.18% |
| 2007 Q4 | -3302.00 CAD | -234.83% |
| 2007 Q3 | 2449.00 CAD | 107.56% |
| 2007 Q1 | 252.94 Thousand CAD | 720.16% |
| 2006 FY | - CAD | 135.91% |
| 2006 Q4 | -40.78 Thousand CAD | -230.71% |
| 2006 Q3 | -12.33 Thousand CAD | 84.5% |
| 2006 Q2 | -79.55 Thousand CAD | 63.27% |
| 2006 Q1 | -216.63 Thousand CAD | -225.8% |
| 2005 Q2 | -151.04 Thousand CAD | 77.17% |
| 2005 Q1 | -661.6 Thousand CAD | -98.33% |
| 2005 FY | - CAD | 70.14% |
| 2005 Q4 | 172.2 Thousand CAD | 258.1% |
| 2005 Q3 | -108.92 Thousand CAD | 27.89% |
| 2004 FY | - CAD | -156.23% |
| 2004 Q1 | -219.16 Thousand CAD | -130.59% |
| 2004 Q2 | -85.18 Thousand CAD | 61.13% |
| 2004 Q3 | 63.09 Thousand CAD | 174.07% |
| 2004 Q4 | -333.58 Thousand CAD | -628.7% |
| 2003 Q1 | -47.98 Thousand CAD | -227.47% |
| 2003 FY | - CAD | -87.91% |
| 2003 Q4 | -95.04 Thousand CAD | -705.94% |
| 2003 Q3 | -11.79 Thousand CAD | 83.59% |
| 2003 Q2 | -71.86 Thousand CAD | -49.77% |
| 2002 FY | - CAD | -126.55% |
| 2002 Q3 | -80.63 Thousand CAD | -24.41% |
| 2002 Q4 | -14.65 Thousand CAD | 81.83% |
| 2002 Q1 | 887.94 Thousand CAD | 1651.34% |
| 2002 Q2 | -64.81 Thousand CAD | -107.3% |
| 2001 Q4 | -57.23 Thousand CAD | -137.83% |
| 2001 Q3 | -24.06 Thousand CAD | -158.86% |
| 2001 Q2 | -9297.00 CAD | 97.26% |
| 2001 Q1 | -338.79 Thousand CAD | -56.98% |
| 2001 FY | - CAD | 190.49% |
| 2000 Q2 | -42.88 Thousand CAD | 90.06% |
| 2000 FY | - CAD | -24.57% |
| 2000 Q1 | -431.47 Thousand CAD | -371.16% |
| 2000 Q4 | -215.81 Thousand CAD | 23.97% |
| 2000 Q3 | -283.84 Thousand CAD | -561.96% |
| 1999 Q4 | -91.57 Thousand CAD | 22.85% |
| 1999 FY | - CAD | -51.64% |
| 1999 Q1 | -244.28 Thousand CAD | -370.39% |
| 1999 Q2 | -65.74 Thousand CAD | 73.09% |
| 1999 Q3 | -118.7 Thousand CAD | -80.56% |
| 1998 FY | - CAD | 58.81% |
| 1998 Q4 | -51.93 Thousand CAD | 58.75% |
| 1998 Q2 | -116.96 Thousand CAD | 0.0% |
| 1998 Q3 | -125.88 Thousand CAD | -7.63% |
| 1997 FY | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Covalon Technologies Ltd. | -3.49 Million CAD | 87.664% |
| Hemostemix Inc. | -1.94 Million CAD | 77.864% |
| Universal Ibogaine Inc. | -4.6 Million CAD | 90.652% |
| Kane Biotech Inc. | -3.23 Million CAD | 86.683% |
| MedMira Inc. | -1.57 Million CAD | 72.692% |
| Marvel Biosciences Corp. | -2.25 Million CAD | 80.874% |
| NervGen Pharma Corp. | -17.72 Million CAD | 97.57% |
| XORTX Therapeutics Inc. | -6.46 Million CAD | 93.341% |